VivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator,
View detailsVVN001 demonstrating clinical and statistical superiority over vehicle in reducing total and sub-regional Corneal Fluorescein Staining scores
View details